BioCentury
ARTICLE | Clinical News

CCX140: Additional Phase II data

July 27, 2015 7:00 AM UTC

Additional data from a 52-week, double-blind, European Phase II trial in 196 evaluable patients with diabetic nephropathy showed that CCX140 plus standard of care (SOC) led to a smaller annual slope d...